메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Xu, Heng (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) Tian, Yan-Na (Jinfiniti Biosciences LLC) Dun, Bo-Ying (Jinfiniti Biosciences LLC) Liu, Hai-Tao (Jinfiniti Biosciences LLC) Dong, Guang-Kuo (Jinfiniti Biosciences LLC) Wang, Jin-Hua (Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University) Lu, Shang-Su (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) Chen, Bo (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) She, Jin-Xiong (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University)
저널정보
아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제11호
발행연도
2014.1
수록면
4,423 - 4,428 (6page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
A novel monoclonal antibody (mAb), known as AC10364, was identified from an antibody library generated by immunization of mice with human carcinoma cells. The mAb recognized proteins in lysates from multiple carcinoma cell lines. Cell cytotoxicity assays showed that AC10364 significantly inhibited cell growth and induced apoptosis in multiple carcinoma cell lines, including Bel/fu, KATO-III and A2780. Compared with mAb AC10364 or chemotherapeutic drugs alone, the combination of mAb AC10364 with chemotherapeutic drugs demonstrated enhanced growth inhibitory effects on carcinoma cells. These results suggest that mAb AC10364 is a promising candidate for cancer therapy.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0